Close Menu

This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority.

NEW YORK – Illumina has proposed offering perpetual, royalty-free licenses to Pacific Biosciences' intellectual property to competitors in the sequencing market in an effort to appease UK regulators who have threatened to block Illumina's planned acquisition of PacBio.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.